Sihuan Pharmaceutical (00460.HK): Xuanzhu Biotech (02575.HK) announced the enrollment of the first patient in the Phase III clinical trial of anindazole sodium for new indications for the eradication of Helicobacter pylori.

Zhixin Finance APP News, Four Rings Pharmaceuticals (00460.HK) announced that its non-wholly-owned subsidiary, Xuanzhu Biotechnology Co., Ltd. (Xuanzhu Biotechnology, stock code: 02575.HK), has successfully completed the enrollment of the first patient in the Phase III clinical trial of its innovative drug Anrailazol Sodium Enteric-coated Tablets (trade name: Anjiuwei) for the eradication of Helicobacter pylori (Hp) using a quadruple therapy with bismuth containing Anrailazol Sodium. This marks the official entry into the substantial execution stage of the critical registration clinical trial.